H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Marinus Pharmaceuticals to $27 from $38 and keeps a Buy rating on the shares post the Q3 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNS: